Imagine being told a life-saving device could actually increase your risk of death—and then discovering hospitals continued to use it anyway. This is the shocking reality for dozens of patients who received a specific heart device, despite known concerns about its higher mortality rate.
Here’s the alarming truth: two of the UK’s top transplant centers, the Freeman Hospital in Newcastle and Harefield Hospital in London, kept implanting a mechanical heart pump called the Medtronic LVAD, even after the NHS raised red flags in 2018. But here’s where it gets even more disturbing: an audit revealed that nearly half of the patients who received this device died within three years, compared to just 15% of those who received a rival product, the Abbott Heartmate III.
And this is the part most people miss: leading cardiologists at both hospitals had financial ties to Medtronic, the device’s manufacturer. While these relationships were known, the hospitals continued to use the pump, questioning the reliability of the NHS data. It wasn’t until 2021 that Medtronic withdrew the device due to safety concerns, citing issues like a higher risk of strokes and a critical malfunction where the pump failed to restart.
Take the tragic story of Greg Marshall, a young man with dreams of joining the Royal Marines. After suffering acute heart failure in 2019, he was fitted with the Medtronic device at the Freeman Hospital. His family claims they were never fully informed of the risks, and a complication during surgery left Greg with a stroke, impairing his movement and speech. A year later, the device failed, and despite efforts to restart it, Greg’s health deteriorated. He passed away in 2023 at just 26 years old. His mother, Tessa, now grapples with guilt, wishing she had done more research. But here’s the controversial question: Should hospitals prioritize patient safety over financial ties or skepticism of data? And should clinicians be required to disclose all potential conflicts of interest more transparently?
LVADs, or Left Ventricular Assist Devices, have been lifesavers for decades, helping patients with weakened hearts survive until a transplant becomes available. For years, hospitals had a choice between the Medtronic HVAD and the Abbott Heartmate III. But by 2018, concerns about the Medtronic device were mounting. The Royal Papworth Hospital in Cambridge stopped using it in February 2018, citing superior outcomes with the Heartmate III. Yet, the Freeman and Harefield hospitals continued to implant the Medtronic device until 2021, despite the growing evidence of its risks.
Here’s another layer to this controversy: The Medicines and Healthcare products Regulatory Agency (MHRA) continued to approve the Medtronic device even after the 2019 NHS analysis, claiming they hadn’t been informed of the data. Between 2018 and 2021, the mortality rate for patients with the Medtronic device was two-and-a-half times higher than for those with the Abbott device. Yet, hospitals defended their decisions, citing 'complex clinical judgments' and a lack of clear evidence that the Medtronic device was inferior.
Prof Stephan Schueler, Greg’s cardiologist at the Freeman, had a decade-long relationship with Medtronic. While he denies any financial incentive influenced his decisions, Greg’s family claims he never disclosed this relationship to them—a potential violation of General Medical Council (GMC) guidelines. Similarly, Dr. André Simon at Harefield had long-standing ties to Medtronic, though the hospital claims these were declared in publications.
But here’s the bigger question: How can patients trust their care when financial ties and data skepticism seem to overshadow safety concerns? Robbie Burns, a patient representative, calls for an external investigation, arguing this tragedy was entirely preventable. 'If I had been in Greg’s position, I’d be asking, 'Why on earth did you do this?'' he says.
Both hospitals express condolences and claim they’re investigating, but the damage is done. Greg’s story is a stark reminder of the need for transparency and accountability in healthcare. What do you think? Should there be stricter regulations around medical device approvals and clinician disclosures? Share your thoughts in the comments below.
